LSD is a psychedelic drug known for its ability to alter perception and psychological functioning by acting on the serotonin 2A receptor. Historically, LSD and other psychedelics were used in psychiatry, and there is currently a resurgence of interest in their therapeutic potential. Recent studies suggest that psychedelic therapy, often involving the patient lying down with closed eyes and...
As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...
Ketamine-assisted psychotherapy (KAP) is considered a promising treatment strategy in psychiatric disorders, combining psychotherapeutic interventions with the rapid-acting pharmacological effects of ketamine towards enhancing outcomes. Although KAP has been practiced for many years across different diagnoses, evidence regarding optimal treatment methods and working mechanisms remains limited...
Despite clinical investigations with psychedelics for severe cases of mood disorders and PTSD and current research suggesting such applicability, research on their application in couples therapy and sex therapy is scarce. The objective of this systematic review was to highlight these drugs as adjuvants for such patients. Literature research was conducted using the terms “couple’s therapy” or...
Psychedelic-assisted therapy shows promise for mental health treatment but faces regulatory, methodological and safety challenges. In this Comment, we propose using artificial intelligence and virtual reality to simulate similar experiences to those produced by traditional psychedelic compounds for use in psychedelic-assisted therapy modalities.
Although commonly used in psychedelic-assisted therapy, the role of therapeutic touch remains loosely defined and ethically sensitive. Gaining insight into how participants experience and interpret touch during psychedelic sessions is essential for informing safe and effective clinical practice. Participants were sampled from a large randomized clinical trial of psilocybin-assisted therapy that...
Psychedelic- and substance-assisted therapies, including MDMA, psilocybin, and ketamine, are gaining attention for conditions such as PTSD and depression, yet their development and implementation remain largely concentrated in high-income settings. This graphical abstract summarizes the central argument of the commentary: while these interventions may hold relevance for global mental health,...
The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the form of fungal fruiting bodies, this...
Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998....
Classic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), have emerged as potent modulators of neuroplasticity and metaplasticity in the adult brain, offering novel therapeutic strategies for neuropsychiatric disorders. Recent findings reveal that beyond their transient psychotropic effects, these compounds activate serotonin 5-HT2A receptors...